脊髓小骨性无氧症1型治疗策略
Laurie M C Kerkhof1,2, Bart P C van de Warrenburg3, Willeke M C van Roon-Mom1,2
1Department of Human Genetics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Biomolecules
|May 27, 2023
概括
1型脊髓脑动症 (SCA1) 是一种由ATXN1基因突变引起的神经退行性疾病. 目前的研究正在探索遗传,药物和细胞替代疗法,以减缓SCA1的进展.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 1型脊髓脑动症 (SCA1) 是一种自体主导的神经退行性疾病,每10万个人中会发生1-2例.
- 由ATXN1基因的扩大CAG重复引起,SCA1导致小脑Purkinje细胞损失,导致协调,平衡和步态障碍.
- 目前,SCA1没有治愈方法,强调需要有效的治疗策略.
研究的目的:
- 审查和总结目前正在研究的1型脊髓小脑动症 (SCA1) 的治疗策略.
- 将SCA1疗法分为遗传学,药理学和细胞替代方法.
- 概述这些策略是如何针对SCA1.1的潜在分子机制的.
主要方法:
- 关于SCA1疗法的临床前和临床研究的文献综述.
- 基于它们的分子标 (ATXN1 RNA,ATAXIN-1蛋白,下游途径或细胞损失) 的治疗策略的分类.
- 综合了关于每个治疗类别的作用机制的信息.
主要成果:
- 已确定针对ATXN1RNA或蛋白质的基因疗法.
- 突出显示了调节疾病途径的药理方法.
- 讨论了细胞替代策略,以恢复丢失的小脑细胞.
- 详细介绍了这些策略的目的是如何减缓疾病的进展.
结论:
- 多种治疗途径,包括遗传,药物和细胞替代疗法,显示出减缓SCA1进展的希望.
- 针对ATXN1RNA,ATAXIN-1蛋白或下游途径是关键策略.
- 恢复丢失的细胞也是潜在的SCA1治疗的关键组成部分.
相关概念视频
01:24Parkinson's Disease: Treatment
308
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
308
01:22Alzheimer's Disease: Treatment
226
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
226
01:20Myasthenia Gravis: Overview and Treatment
1.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.7K